Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reaffirmed at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $38.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 129.61% from the company’s previous close.

Several other analysts have also issued reports on SNDX. UBS Group restated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th. JPMorgan Chase & Co. lowered their price objective on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.80.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $16.55 on Tuesday. Syndax Pharmaceuticals has a 12 month low of $12.99 and a 12 month high of $25.59. The company has a current ratio of 6.77, a quick ratio of 6.44 and a debt-to-equity ratio of 38.95. The business’s 50 day simple moving average is $18.98 and its 200 day simple moving average is $20.47. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -6.59 and a beta of 0.42.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The firm had revenue of $72.79 million for the quarter, compared to the consensus estimate of $79.36 million. During the same period last year, the company posted ($0.83) earnings per share. Syndax Pharmaceuticals’s revenue for the quarter was up 91.8% on a year-over-year basis. Sell-side analysts forecast that Syndax Pharmaceuticals will post -2.03 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter worth $197,177,000. Bank of America Corp DE bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth $88,426,000. Elmind Capital LP purchased a new position in shares of Syndax Pharmaceuticals in the second quarter valued at $40,550,300. Trails Edge Capital Partners LP purchased a new position in shares of Syndax Pharmaceuticals in the second quarter valued at $24,264,600. Finally, Algert Global LLC grew its position in shares of Syndax Pharmaceuticals by 13.2% in the second quarter. Algert Global LLC now owns 1,051,465 shares of the company’s stock valued at $22,985,000 after purchasing an additional 122,897 shares in the last quarter.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Axatilimab was well tolerated in the MAXPIRe trial, with a safety profile comparable to placebo and no new safety signals. The drug remains in multiple cGVHD trials, with results expected later this year and in early 2028. Syndax Announces Topline Results from MAXPIRe Phase 2 Trial
• Neutral Sentiment: The Phase 2 MAXPIRe study evaluated axatilimab in IPF, a progressive lung disease. Syndax reported topline results but did not provide evidence that the treatment improved the trial’s primary lung-function measure. Syndax Announces MAXPIRe Topline Results
• Negative Sentiment: MAXPIRe failed to meet its primary endpoint, the annualized rate of decline in forced vital capacity (FVC). Syndax is ending development of axatilimab in IPF, eliminating a potential indication and likely reducing the drug’s long-term revenue opportunity. Syndax MAXPIRe Trial Misses Primary Endpoint
• Negative Sentiment: The trial failure triggered a sharp selloff as investors reassessed Syndax’s pipeline value and became more dependent on the company’s cGVHD programs for future growth. The setback is particularly important because Syndax remains loss-making and has reported quarterly revenue below analyst expectations. Syndax IPF Trial Misses Endpoint

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.